Holen Sie sich die Stockscreener-App
0.6798
6.48%
0.0414
Schlusskurs vom Vortag:
$0.6384
Offen:
$0.65
24-Stunden-Volumen:
354.78K
Relative Volume:
0.22
Marktkapitalisierung:
$111.15M
Einnahmen:
$126.33M
Nettoeinkommen (Verlust:
$-82.68M
KGV:
-1.133
EPS:
-0.6
Netto-Cashflow:
$-79.98M
1W Leistung:
-11.20%
1M Leistung:
-18.36%
6M Leistung:
-31.97%
1J Leistung:
-10.67%
1-Tages-Spanne:
$0.64
$0.6865
1-Wochen-Bereich:
$0.623
$0.7806
52-Wochen-Spanne:
$0.54
$1.53
Seres Therapeutics Inc Stock (MCRB) Company Profile
Firmenname
Seres Therapeutics Inc
Sektor
Branche
Telefon
617 945 9626
Adresse
200 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie MCRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
0.6798 | 111.15M | 126.33M | -82.68M | -79.98M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
510.86 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
670.03 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
602.20 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.01 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.61 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-24 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-04-21 | Eingeleitet | JP Morgan | Neutral |
| 2021-07-23 | Herabstufung | Goldman | Neutral → Sell |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-03-05 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-11 | Hochstufung | Jefferies | Hold → Buy |
| 2019-04-30 | Eingeleitet | Jefferies | Hold |
| 2018-10-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-08-04 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-01 | Bestätigt | FBR & Co. | Outperform |
| 2016-08-12 | Bestätigt | FBR Capital | Outperform |
| 2016-08-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Bestätigt | H.C. Wainwright | Buy |
| 2016-07-29 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-03-30 | Eingeleitet | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | Guggenheim | Buy |
| 2016-01-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-10-22 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-07-21 | Eingeleitet | Goldman | Neutral |
| 2015-07-21 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Seres Therapeutics Inc Aktie (MCRB) Neueste Nachrichten
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2024 Earnings Call Transcript - Insider Monkey
Seres Therapeutics Advances SER-155 Program with FDA Support - TipRanks
Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and ... - Yahoo Finance
Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and Strategic Developments - GuruFocus.com
Seres Therapeutics Earnings Call: Progress Amid Uncertainty - TipRanks
Seres Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Evaluating MCRB’s financial ratios for a profitable investment - US Post News
Seres Therapeutics, Inc. SEC 10-K Report - TradingView
Earnings call transcript: Seres Therapeutics Q4 2024 financial results disappoint - Investing.com India
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - The Manila Times
Seres Therapeutics Receives FDA Feedback Supporting SER-155 Study Plans for Bloodstream Infection Reduction in Allogeneic Hematopoietic Stem Cell Transplant Patients - Nasdaq
Seres Therapeutics Breakthrough Drug Cuts Infection Risk by 77% in Stem Cell Transplants - StockTitan
Seres Therapeutics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to “Hold” - Defense World
Seres Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Seres Therapeutics (NASDAQ: MCRB) Stock Gains Momentum Ahead of Q4 Earnings - DRP Journal
Seres Therapeutics (MCRB) Expected to Announce Earnings on Thursday - Defense World
Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsight - GlobeNewswire Inc.
Seres Therapeutics to Announce Fourth Quarter and Full Year - GlobeNewswire
Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025 - The Manila Times
When Will Seres Therapeutics Reveal Its 2024 Financial Performance? - StockTitan
FDA supports Seres Therapeutics’ study endpoint - Investing.com India
Seres Therapeutics receives feedback from FDA on SER-155 development approach - TipRanks
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach - The Manila Times
FDA supports Seres Therapeutics' study endpoint - Investing.com
FDA supports Seres Therapeutics’ study endpoint By Investing.com - Investing.com Australia
Seres Therapeutics Receives Feedback From FDA on SER-155 - GlobeNewswire
Can Seres' SER-155 Reduce Post-Transplant Infections by 77%? FDA Backs Key Trial Endpoint - StockTitan
Seres Therapeutics (MCRB) Expected to Announce Earnings on Tuesday - Defense World
5 Best Microbiome Companies (March 2025) - Securities.io
Seres Therapeutics (MCRB) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
Seres Therapeutics, Inc.'s (NASDAQ:MCRB) market cap dropped US$15m last week; individual investors who hold 50% were hit as were institutions - Simply Wall St
Seres Therapeutics, Inc. Receives Feedback from Fda on Ser-155 Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct) Development Approach - Marketscreener.com
Seres Therapeutics Announces CMO Resignation in March 2025 - TipRanks
Investor Network: Seres Therapeutics Inc to Host Earnings Call - ACCESS Newswire
Seres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com to “Sell” - Defense World
Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Purchased by Vontobel Holding Ltd. - MarketBeat
Seres Therapeutics executive sells shares worth $3,579 By Investing.com - Investing.com Nigeria
Seres Therapeutics officer sells $3,203 in stock By Investing.com - Investing.com South Africa
Seres Therapeutics, Inc. (NASDAQ:MCRB) CEO Eric D. Shaff Sells 12,726 Shares - MarketBeat
Seres Therapeutics CEO Eric Shaff sells $10,314 in stock - Investing.com India
Seres Therapeutics EVP sells $2,704 in stock By Investing.com - Investing.com South Africa
Seres Therapeutics CEO Eric Shaff sells $10,314 in stock By Investing.com - Investing.com South Africa
Seres Therapeutics exec Thomas Desrosier sells $3,485 in stock - Investing.com
Seres Therapeutics executive sells shares worth $3,579 - Investing.com
Seres Therapeutics EVP sells $2,704 in stock - Investing.com
Seres Therapeutics officer sells $3,203 in stock - Investing.com
Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Stock Crosses Below 50-Day Moving AverageWhat's Next? - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Upgraded at StockNews.com - Defense World
Finanzdaten der Seres Therapeutics Inc-Aktie (MCRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.28%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):